Canada's MediPharm Labs Q2 revenue rises 11% on international growth

Medipharm Labs

13/08/2026 12:47

Overview
Canada pharmaceutical cannabinoid maker's Q2 revenue rose 11% sequentially, driven by international medical business
Adjusted EBITDA for Q2 reached C$0.9 mln, strongest since 2019
Company returned to positive net income in Q2 after net loss in prior yr

Outlook
Company plans to launch new product formats and formulations in H2 2026
MediPharm expects restructuring actions to deliver over C$1 mln in annualized savings
Company aims to grow international medical revenue and reduce costs to drive long-term value

Result Drivers
INTERNATIONAL MEDICAL GROWTH - Co said international medical revenue rose 26% sequentially, with German sales up 45% after new product launches
COST REDUCTIONS - Co attributed 44% decrease in operating expenses to restructuring actions completed in Q1 2026
CANADIAN REIMBURSEMENT IMPACT - Co said Canadian medical cannabis revenue fell 23% sequentially after Veterans Affairs Canada cut reimbursement rates, but overall profitability was mitigated through efficiencies and other revenue opportunities

Company press release: ID:nGNX48WyT1

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
C$10 mln
 
Q2 Adjusted EBITDA
 
C$900,000
 
Q2 Gross Profit
 
C$4.30 mln
 

Reuters Recommended Reads
Aug 11 - Canada's Organigram Q3 revenue beats on Sanity acquisition; CFO to exit
Aug 12 - Cannabis grower Ascend Wellness' Q2 revenue rises after retail expansion
Aug 11 - Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)